Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,346 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Terminated Phase 2 Interventional Results available

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

NCT02915263
View directory record Official record
Conditions
Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
Interventions
IGIV-C, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

NCT04152083
View directory record Official record
Conditions
Migraine
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 12, 2026, 2:35 PM EDT
Recruiting Phase 2 Interventional

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863
View directory record Official record
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions
Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Biological · Other · Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

NCT00843193
View directory record Official record
Conditions
Asthma
Interventions
INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

NCT01508936
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
66
States / cities
Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine

NCT00000720
View directory record Official record
Conditions
HIV Infections
Interventions
Globulin, Immune, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
48
States / cities
Downey, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 12, 2026, 2:35 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT04990440
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Bermekimab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 12, 2026, 2:35 PM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

NCT02929576
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, Placebo, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
6
States / cities
Topeka, Kansas • Metairie, Louisiana • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects

NCT03239379
View directory record Official record
Conditions
Safety and Tolerability in Healthy Subjects
Interventions
BNZ132-1-40, Placebo
Drug
Lead sponsor
Bioniz Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 12, 2026, 2:35 PM EDT
Terminated Phase 3 Interventional Results available

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

NCT02263508
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec, Pembrolizumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 95 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 12, 2026, 2:35 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Sjogrens Syndrome Measured by Ultrasound

NCT03411850
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Orencia, Placebo
Biological · Other
Lead sponsor
Arthritis & Rheumatism Associates, P.C.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 12, 2026, 2:35 PM EDT
Active, not recruiting Phase 3 Interventional

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions
Lecanemab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 12, 2026, 2:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 12, 2026, 2:35 PM EDT
Terminated Phase 2 Interventional Results available

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

NCT03068468
View directory record Official record
Conditions
Supranuclear Palsy, Progressive
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 12, 2026, 2:35 PM EDT
Terminated Phase 2 Interventional Results available

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

NCT01364389
View directory record Official record
Conditions
Polymyalgia Rheumatica, Inflammatory Diseases
Interventions
AIN457, ACZ885, Prednisone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients

NCT01426789
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
16
States / cities
Phoenix, Arizona • Tuscon, Arizona • Anahiem, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 12, 2026, 2:35 PM EDT
Terminated Phase 3 Interventional Results available

Inositol to Reduce Retinopathy of Prematurity

NCT01954082
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
myo-Inositol 5% Injection, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 12, 2026, 2:35 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

NCT07647510
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Claseprubart, Placebo, Claseprubart, Placebo
Drug · Combination Product
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Pasadena, California • Boca Raton, Florida • Fayetteville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers

NCT00829582
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ETI-204, "Anthim", placebo
Drug · Other
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy

NCT00948610
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Remicade
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 12, 2026, 2:35 PM EDT
Terminated Phase 4 Interventional Results available

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

NCT00626574
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Epoetin alfa, Saline
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 12, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

NCT03985410
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions
ETX2514, Placebo, moxifloxacin
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 12, 2026, 2:35 PM EDT